Literature DB >> 21185632

HCV infection and the incidence of CKD.

Adeel A Butt1, Xiaoqiang Wang, Linda F Fried.   

Abstract

BACKGROUND: The risk of hepatitis C virus (HCV) infection upon incident chronic kidney disease (CKD) in the presence of traditional risk factors and renal-modifying therapy is not well known. STUDY
DESIGN: National cohort study. SETTING & PARTICIPANTS: HCV-infected and -uninfected veterans in ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) in 2001-2006. PREDICTOR: HCV infection. OUTCOMES: Incident CKD stages 3-5.
RESULTS: We identified 18,002 patients with HCV infection and 25,137 controls with estimated glomerular filtration rate >60 mL/min/1.73 m(2) at baseline. HCV-infected patients had a lower prevalence of several CKD risk factors, including diabetes (22.9% vs 26.6%), hypertension (52.4% vs 60.8%), and dyslipidemia (39.3% vs 73.9%; P < 0.001). HCV infection was associated with a higher risk of developing CKD stages 3-5 (HR, 1.30; 95% CI, 1.23-1.37). Increasing age, hypertension, and diabetes were associated with significantly higher risks of developing CKD in HCV-infected patients and controls. Decompensated liver disease was a strong predictor of CKD in HCV-infected patients (HR, 3.37; 95% CI, 3.10-3.66) and HCV-uninfected controls (HR, 2.04; 95% CI, 1.84-2.25). In Kaplan-Meier analysis, HCV-infected persons had a shorter time to CKD. LIMITATIONS: Lack of proteinuria data; small number of women.
CONCLUSIONS: HCV infection is associated with higher risk and shorter time to CKD despite having a lower prevalence of many CKD risk factors. HCV-infected persons should have targeted monitoring for the development and progression of CKD. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21185632     DOI: 10.1053/j.ajkd.2010.09.023

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  33 in total

Review 1.  Hepatitis C virus infection and kidney disease: a meta-analysis.

Authors:  Fabrizio Fabrizi; Paul Martin; Vivek Dixit; Piergiorgio Messa
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

2.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

3.  Association between hepatitis C virus and chronic kidney disease: heterogeneity begets heterogeneity.

Authors:  Gregory M Lucas
Journal:  Kidney Int       Date:  2017-09       Impact factor: 10.612

4.  Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals.

Authors:  Gregory M Lucas; Yuezhou Jing; Mark Sulkowski; Alison G Abraham; Michelle M Estrella; Mohamed G Atta; Derek M Fine; Marina B Klein; Michael J Silverberg; M John Gill; Richard D Moore; Kelly A Gebo; Timothy R Sterling; Adeel A Butt
Journal:  J Infect Dis       Date:  2013-07-31       Impact factor: 5.226

5.  Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.

Authors:  A A Butt; P Yan; O S Shaikh; M S Freiberg; V Lo Re; A C Justice; K E Sherman
Journal:  J Viral Hepat       Date:  2014-12-18       Impact factor: 3.728

6.  A population-based study on the prevalence and incidence of chronic kidney disease in the Netherlands.

Authors:  Jan C van Blijderveen; Sabine M Straus; Robert Zietse; Bruno H Stricker; Miriam C Sturkenboom; Katia M Verhamme
Journal:  Int Urol Nephrol       Date:  2013-09-27       Impact factor: 2.370

Review 7.  Extrahepatic manifestations of chronic hepatitis C virus infection.

Authors:  Patrice Cacoub; Cloe Comarmond; Fanny Domont; Léa Savey; Anne C Desbois; David Saadoun
Journal:  Ther Adv Infect Dis       Date:  2016-02

8.  Liver fibrosis progression in hepatitis C virus infection after seroconversion.

Authors:  Adeel A Butt; Peng Yan; Vincent Lo Re; David Rimland; Matthew B Goetz; David Leaf; Matthew S Freiberg; Marina B Klein; Amy C Justice; Kenneth E Sherman
Journal:  JAMA Intern Med       Date:  2015-02       Impact factor: 21.873

9.  Renal function is impaired in normotensive chronic HCV patients: role of insulin resistance.

Authors:  Angela Sciacqua; Maria Perticone; Eliezer J Tassone; Antonio Cimellaro; Benedetto Caroleo; Sofia Miceli; Michele Andreucci; Anna Licata; Giorgio Sesti; Francesco Perticone
Journal:  Intern Emerg Med       Date:  2015-11-23       Impact factor: 3.397

10.  Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Authors:  Vincent Lo Re; Charitha Gowda; Paul N Urick; Joshua T Halladay; Amanda Binkley; Dena M Carbonari; Kathryn Battista; Cassandra Peleckis; Jody Gilmore; Jason A Roy; Jalpa A Doshi; Peter P Reese; K Rajender Reddy; Jay R Kostman
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-05       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.